228710-83-6

Basic information

• Product Name: 2-chloro-1-(6-(2,5-dimethyl-1H-pyrrol-1-yl)pyridin-3-yl)ethanone
• Synonyms: 2-chloro-1-(6-(2,5-dimethyl-1H-pyrrol-1-yl)pyridin-3-yl)ethanone
• CAS NO: 228710-83-6
• Molecular Formula: C₁₃H₁₃ClN₂O
• Molecular Weight: 248.70812
• Mol File: 228710-83-6.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-chloro-1-(6-(2,5-dimethyl-1H-pyrrol-1-yl)pyridin-3-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-1-(6-(2,5-dimethyl-1H-pyrrol-1-yl)pyridin-3-yl)ethanone(228710-83-6)
• EPA Substance Registry System: 2-chloro-1-(6-(2,5-dimethyl-1H-pyrrol-1-yl)pyridin-3-yl)ethanone(228710-83-6)

Safety Data

• Hazardous Substances Data: 228710-83-6(Hazardous Substances Data)

Upstream product

• 228710-82-5 5-bromo-2-(2,5-dimethyl-pyrrol-1-yl)-pyridine 
• 67442-07-3 2-chloro-N-methoxy-N-methylacetamide 
• 110-13-4 2,5-hexanedione 

Relevant articles and documents

MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN

The present invention relates to use of a compound of formula (I), (Ia), or (Ib), wherein A, B, Z, R1and R2 have the meanings given in the specification, as a medicament for the treatment of a number of pain conditions, particularly chronic or nociceptive

NOVEL SALT FORM OF A DOPAMINE AGONIST

This invention relates to a novel salt form of dopamine agonist 5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine (I): More particularly, this invention relates to 5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine di-(1 S)-camphorsulfonate (di-S-camsylate) and to processes for the preparation of, intermediates used in the preparation of, compositions containing, and the uses of this salt.

AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS

The present invention provides for compounds of formula (I) which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.